Ron-Guerrero CS, Ron-Magaña AL

Language: Spanish
References: 14
Page: 231-236
PDF size: 344.57 Kb.

ABSTRACT

We report the case of a 44-year-old woman with a diagnosis of chronic myeloid leukemia since October 2006. Her prognostic index of Sokal and Hasford was calculated, with a low risk result in both. The hematological remission was achieved in 6 weeks. He received imatinib for 55 months, then nilotinib for 37 months, total 92 months of treatment with tyrosine kinase inhibitors. The patient remains in molecular remission greater than 44 months without treatment (undetectable transcripts) until the moment of this report.

REFERENCES

1. O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994.

2. Hochhaus A, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917.

3. Hehlmann R, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non- CML determinants. Leukemia 2017;31:2398.

4. Wang J, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 2015;125:2771.

5. Kantarjian HM, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123.

6. Cortes JE, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486.

7. Cortes JE, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial. J Clin Oncol 2018;36:231.

8. Kwak JY, et al. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clin Cancer Res 2017;23:7180.

9. Saussele S, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:1880.

10. Apperley JF. TWIST it but don’t spin it. Blood 2013;122:470.

11. Etienne G, et al. Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia. J Clin Oncol 2017;35:298.

12. Ross DM, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515.

13. Rea D, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 2017;129:846.

14. Hochhaus A, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 2017;31:1525.a